BIOMAT Database Logo BIOMAT Database Logo

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. 2000

P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Department of Medical Psychology, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands. p.t.nieuwkerk@amc.uva.nl

OBJECTIVE To compare the impact on quality of life (QoL) of treatment with ritonavir (RTV)/saquinavir (SQV) versus RTV/SQV/stavudine (d4T) in asymptomatic [Centers for Disease Control (CDC) class A] and symptomatic HIV-infected patients (CDC B and C) who did or did not receive antiretroviral therapy (ARVT) before entry into the study. METHODS A multicenter randomized clinical trial. METHODS Protease inhibitor- and d4T-naive patients were allocated to RTV/SQV (n = 84) versus RTV/SQV/d4T (n = 83). METHODS Changes from baseline in QoL assessed by the Medical Outcomes Study Health Survey for HIV (MOS-HIV) and a symptom checklist administered at baseline and after 12, 24, 36 and 48 weeks. RESULTS Changes in QoL were comparable in both treatments, although more neuropathy was reported in the RTV/SQV/d4T group. QoL improved significantly in both groups regarding health distress, energy/fatigue, mental health, health perceptions, physical function and overall QoL, despite an increase in reported symptoms. More favourable changes in cognitive and social function were observed in symptomatic compared with asymptomatic patients, with symptomatic patients showing an improvement and asymptomatic patients showing a decline in function after baseline. ARVT-naive patients showed more favourable changes in mental health, health distress and social function compared with patients with previous ARVT. CONCLUSIONS RTV/SQV and RTV/SQV/d4T were equally effective in improving the QoL of patients over 48 weeks, despite an increase in reported symptoms. Symptomatic patients reported more QoL benefit than asymptomatic patients, and ARVT-naive patients benefitted more than those with previous ARVT. The impact on patients' QoL should be considered in the search for the optimal management of HIV infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
March 2000, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.
November 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
January 2005, Antiviral therapy,
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.
August 1999, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.
May 2000, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
January 2001, HIV clinical trials,
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
March 1997, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.
February 1998, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group.
August 1998, AIDS (London, England),
P T Nieuwkerk, and E H Gisolf, and R Colebunders, and A W Wu, and S A Danner, and M A Sprangers
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.
October 2002, HIV medicine,
Copied contents to your clipboard!